Resource use and costs in systolic heart failure according to disease severity: a pooled analysis from the German Competence Network Heart Failure
Systolic chronic heart failure (CHF) is currently one of the most prevalent cardiac diseases. The present analysis sought to estimate the 1-year disease-related resource use and associated management costs of patients with CHF.
Subject and methods
A total of 2,710 individuals with systolic CHF [mean age 62.9 years ± 13.6, 25.2% female, New York Heart Association (NYHA) I–IV] were included from the German Competence Network Heart Failure. Disease-related resource use was assessed with regard to outpatient contacts with physicians, hospitalizations including rehabilitation stays and drug utilization.
During 1 year, patients had on average 6.1 contacts with their general practitioner, 1.7 contacts with cardiologists and 0.8 hospital stays per year. Overall disease-related health care costs per patient were calculated at 3,150 € per year. The largest component related to hospitalizations (2,328 €, 74%), while costs of rehabilitation (294 €, 9%), medication (290 €, 9%) and outpatient contacts (238 €, 8%) were considerably lower. Compared with 2,474 € in NYHA class I, there was a cost increase in NYHA II, III and IV of 14, 48 and 71%, respectively. About 76% of this cost increase resulted from augmented hospital (inpatient) resource use.
The present analysis demonstrates a high disease-related resource consumption of heart failure care. In particular, patients in higher NYHA classes require increased inpatient resources. Hence, improved treatment strategies need to be developed to optimize care thus reducing hospitalization rates.
KeywordsEconomic evaluation Heart failure Resource use Costs
This work was supported by the Competence Network of Heart Failure funded by the Federal Ministry of Education and Research (BMBF), FKZ 01GI0205.
Conflict of interest
The authors declare that they have no conflict of interest.
- Brouwer W, Rutten F, Koopmanschap M (2001) Costing in economic evaluations. In: Drummond M, McGuire A (eds) Economic evaluation in health care: merging theory with practice. Oxford University Press, Oxford, pp 68–93Google Scholar
- Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388–2442PubMedCrossRefGoogle Scholar
- Luce BR, Manning WG, Siegel JE, Lipscomb J (1996) Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russel LB, Weinstein MC (eds) Cost-effectiveness in health and medicine. Oxford University Press, New York, pp 176–213Google Scholar
- Schwabe U, Paffrath D (eds) (2010) Arzneiverordnungs-Report 2010: Aktuelle Daten, Kosten, Trends und Kommentare. Springer, BerlinGoogle Scholar
- Szucs TD (2003) Gesundheitsökonomische Aspekte der chronischen Herzinsuffizienz. Teil 1: Krankheitslast und ökonomische Bewertung. Schweiz Arzteztg 84:2431–2435Google Scholar